Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus: A systematic review and meta-analysis

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Hu, Qiang ^a   Sun, Tian Tian ^a   Hong, Jie ^a   Fang, Jing Yuan ^a   Xiong, Hua ^a   Meltzer, Stephen J ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXLANSOPRAZOLE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREND STUDY; ADENOCARCINOMA; COMPLICATION; DISEASE COURSE; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; ODDS RATIO; PATHOLOGY; RISK;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS, PEPTIC; HUMANS; ODDS RATIO; PROTON PUMP INHIBITORS; RISK;

EID: 85009154380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169691     Document Type: Article

References (45)

1. Alsalahi O, Dobrian AD. Proton Pump Inhibitors: The Culprit for Barrett's Esophagus? Frontiers in oncology. 2014; 4:373. Epub 2015/01/27. Pub Med Central PMCID: PMCPmc4288325. doi: 10.3389/fonc.2014.00373 PMID: 25621278
2. Fan X, Snyder N. Prevalence of Barrett's esophagus in patients with or without GERD symptoms: role of race, age, and gender. Digestive diseases and sciences. 2009; 54(3):572-7. Epub 2008/07/26. doi: 10.1007/s10620-008-0395-7 PMID: 18654849
3. Kastelein F, Spaander MC, Biermann K, Vucelic B, Kuipers EJ, Bruno MJ. Role of acid suppression in the development and progression of dysplasia in patients with Barrett's esophagus. Digestive diseases. 2011; 29(5):499-506. Epub 2011/11/19. doi: 10.1159/000331513 PMID: 22095018
4. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nature reviews Cancer. 2010; 10(2):87-101. Pub Med Central PMCID: PMC2879265. doi: 10.1038/nrc2773 PMID: 20094044
5. Abrams JA, Sharaiha RZ, Gonsalves L, Lightdale CJ, Neugut AI. Dating the rise of esophageal adenocarcinoma: analysis of Connecticut Tumor Registry data, 1940-2007. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011; 20(1):183-6. Pub Med Central PMCID: PMC3018857.
6. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. Journal of the National Cancer Institute. 2008; 100(16):1184-7. Pub Med Central PMCID: PMC2518165. doi: 10.1093/jnci/djn211 PMID: 18695138
7. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. Journal of the National Cancer Institute. 2005; 97(2):142-6. doi: 10.1093/jnci/dji024 PMID: 15657344
8. Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K, et al. Do proton pump inhibitors protect against cancer progression in GERD? Surgery today. 2013; 43(8):831-7. Epub 2012/11/01. doi: 10.1007/s00595-012-0395-2 PMID: 23111465
9. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase- 1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. The Journal of pharmacology and experimental therapeutics. 2009; 331(1):255-64. doi: 10.1124/jpet. 109.152702 PMID: 19628634
10. Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflammation research: official journal of the European Histamine Research Society [et al]. 2006; 55(11):476-80.
11. Maity P, Bindu S, Choubey V, Alam A, Mitra K, Goyal M, et al. Lansoprazole protects and heals gastric mucosa from non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy by inhibiting mitochondrial as well as Fas-mediated death pathways with concurrent induction of mucosal cell renewal. The Journal of biological chemistry. 2008; 283(21):14391-401. doi: 10.1074/jbc.M800414200 PMID: 18375387
12. Kuipers EJ. Barrett's oesophagus, proton pump inhibitors and gastrin: the fog is clearing. Gut. 2010; 59 (2):148-9. Epub 2010/02/24. doi: 10.1136/gut.2009.191403 PMID: 20176635
13. Dall'Olmo L, Fassan M, Dassie E, Scarpa M, Realdon S, Cavallin F, et al. Role of proton pump inhibitor on esophageal carcinogenesis and pancreatic acinar cell metaplasia development: an experimental in vivo study. PloS one. 2014; 9(11):e112862. Epub 2014/11/22. Pub Med Central PMCID: PMCPmc4240576. doi: 10.1371/journal.pone.0112862 PMID: 25415190
14. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014; 63(8):1229-37. Epub 2013/11/14. Pub Med Central PMCID: PMCPmc4199831. doi: 10. 1136/gutjnl-2013-305997 PMID: 24221456
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010; 25(9):603-5. doi: 10.1007/s10654-010-9491-z PMID: 20652370
16. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiology and drug safety. 2007; 16(3):241-9. doi: 10.1002/pds.1357 PMID: 17252614
17. Suissa S, Dell'aniello S, Vahey S, Renoux C. Time-window bias in case-control studies: statins and lung cancer. Epidemiology. 2011; 22(2):228-31. doi: 10.1097/EDE.0b013e3182093a0f PMID: 21228697
18. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. The Medical journal of Australia. 2004; 180(8):387-91. Epub 2004/04/20. PMID: 15089728
19. Jung KW, Talley NJ, Romero Y, Katzka DA, Schleck CD, Zinsmeister AR, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. The American journal of gastroenterology. 2011; 106(8):1447-55; quiz 56. Pub Med Central PMCID: PMC3150349. doi: 10.1038/ajg.2011.130 PMID: 21483461
20. Sterne JAJEM, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001; 323(7304):101-5. PMID: 11451790
21. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2009; 7(12):1299-304. Epub 2009/06/16. Pub Med Central PMCID: PMCPmc2789910.
22. Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2013; 11(4):382-8. Epub 2012/12/04.
23. Altawil JIB, Jinjuvadia R, Antaki F. Can progression to dysplasia in Barrett's esophagus be prevented by proton pump inhibitors? Am J Gastroenterol. 2011; 106:S31.
24. de Jonge PJ, Steyerberg EW, Kuipers EJ, Honkoop P, Wolters LM, Kerkhof M, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. The American journal of gastroenterology. 2006; 101(7):1421-9. Epub 2006/07/26. doi: 10.1111/j.1572-0241.2006.00626.x PMID: 16863542
25. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010; 138(7):2260-6. Epub 2010/03/02. Pub Med Central PMCID: PMCPmc2883678. doi: 10.1053/j.gastro. 2010.02.045 PMID: 20188100
26. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Alimentary pharmacology & therapeutics. 2014; 39(9):984-91. Epub 2014/03/13.
27. Masclee GMCP, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open. 2015; 29(5):1.
28. Hvid-Jensen F, Drewes AM, Funch-Jensen P. Letter: Proton pump inhibitor usage still seems to reduce the risk of high-grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus-Authors' reply. Alimentary Pharmacology and Therapeutics. 2014; 40(7):860-1. doi: 10.1111/apt.12931 PMID: 25185739
29. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer research. 1998; 58(14):2929-34. Epub 1998/07/29. PMID: 9679948
30. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. Journal of the National Cancer Institute. 2002; 94(6):422-9. Epub 2002/03/21. PMID: 11904314
31. Falk GW, Buttar NS, Foster NR, Ziegler KLA, De Mars CJ, Romero Y, et al. A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. Gastroenterology. 2012; 143(4):917-26.e1. doi: 10.1053/j.gastro.2012.06.044 PMID: 22796132
32. Lagergren JBR, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. The New England journal of medicine. 1999; 340(11):825-31. doi: 10. 1056/NEJM199903183401101 PMID: 10080844
33. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006; 55(11):1538-44. Epub 2006/06/21. Pub Med Central PMCID: PMCPmc1860118. doi: 10.1136/gut.2005.086579 PMID: 16785284
34. Alexandre L, Clark AB, Bhutta HY, Holt S, Lewis MP, Hart AR. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology. 2014; 146(3):661-8. Epub 2013/12/10. doi: 10.1053/j.gastro.2013.11.046 PMID: 24315828
35. Garnett WR. History of acid suppression: focus on the hospital setting. Pharmacotherapy. 2003; 23(10 Pt 2):56s-60s. Epub 2003/11/01.
36. Nasr AO, Dillon MF, Conlon S, Downey P, Chen G, Ireland A, et al. Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux. Surgery. 2012; 151 (3):382-90. Epub 2011/10/25. doi: 10.1016/j.surg.2011.08.021 PMID: 22019500
37. Huo X, Juergens S, Zhang X, Rezaei D, Yu C, Strauch ED, et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kappaB activation in benign Barrett's epithelial cells. American journal of physiology Gastrointestinal and liver physiology. 2011; 301(2):G278-86. Epub 2011/06/04. Pub Med Central PMCID: PMCPmc3154602. doi: 10.1152/ajpgi.00092.2011 PMID: 21636532
38. Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, et al. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. The American journal of gastroenterology. 2010; 105(5):1039-45. Epub 2009/11/12. Pub Med Central PMCID: PMCPmc3139948. doi: 10.1038/ajg.2009.629 PMID: 19904251
39. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology. 2003; 124(3):615-25. Epub 2003/03/04. doi: 10.1053/gast.2003.50091 PMID: 12612900
40. Green DA, Mlynarczyk CM, Vaccaro BJ, Capiak KM, Quante M, Lightdale CJ, et al. Correlation between serum gastrin and cellular proliferation in Barrett's esophagus. Therapeutic advances in gastroenterology. 2011; 4(2):89-94. Epub 2011/06/23. Pub Med Central PMCID: PMCPmc3105623. doi: 10.1177/1756283X10392444 PMID: 21694810
41. Krarup AL, Olesen SS, Funch-Jensen P, Gregersen H, Drewes AM. Proximal and distal esophageal sensitivity is decreased in patients with Barrett's esophagus. World journal of gastroenterology: WJG. 2011; 17(4):514-21. Pub Med Central PMCID: PMC3027019. doi: 10.3748/wjg.v17.i4.514 PMID: 21274382
42. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. The Lancet. 2006; 367(9528):2086-100.
43. Zagari RM, Law GR, Fuccio L, Pozzato P, Forman D, Bazzoli F. Dyspeptic Symptoms and Endoscopic Findings in the Community: The Loiano-Monghidoro Study. The American journal of gastroenterology. 2010; 105(3):565-71. doi: 10.1038/ajg.2009.706 PMID: 20010920
44. Spechler SJ SP, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. Gastroenterology. 2011; 140 (3):1084-91. doi: 10.1053/j.gastro.2011.01.030 PMID: 21376940
45. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014; 63(1):7-42. doi: 10.1136/gutjnl-2013-305372 PMID: 24165758